目的 探讨胃癌组织中膜联蛋白A2(ANXA2)表达与胃癌临床病理特征及预后的关系.方法 对96例胃癌手术组织及配对癌旁组织石蜡标本进行免疫组织化学染色(IHC),检测ANXA2、基质金属蛋白酶-2(MMP-2)、MMP-7、MMP-9、基质金属蛋白酶组织抑制剂-1(TIMP-1)的染色,分析其中的关系;收集胃癌患者临床病理指标,分析ANXA2与胃癌临床病理特征的关系;所有患者进行随访,进行预后分析.结果 胃癌组织中ANXA2表达阳性率为78.13％(75/96),比癌旁组织的阳性表达率[28.13％(27/96)]增高(x2 =48.188,P＜0.01);MMP-2、MMP-7、MMP-9在胃癌组织中阳性表达率分别为76.04％(73/96)、65.63％(63/96)、85.42％(82/96),均比癌旁组织的阳性表达率[20.83％(20/96)、32.29％(31/96)、21.88％ (21/96)]增高(x2=58.578,P＜0.01;x2=21.343,P＜0.01;x2 =77.935,P＜0.01),TIMP-1在胃癌组织中表达阳性率为33.33％(32/96),明显低于癌旁组织[60.42％(58/96),x2=14.139,P＜0.01].ANXA2阳性表达与胃癌患者淋巴结转移、脉管瘤栓有关(x2=40.253,P＜0.01;x2 =5.704,P＜0.05);Kaplan-Meier生存分析显示,ANXA2阴性表达的胃癌患者平均生存期为(42.22±4.50)个月,比ANXA2阳性者的平均生存期[(26.24±2.30)个月]明显延长(x2=7.660,P＜0.01).相关分析显示,胃癌组织中ANXA2与MMP-2、MMP-7呈正相关(r =0.274 8、P＜0.01;r =0.317 5,P＜0.01),ANXA2与TIMP-1呈负相关(r=-0.262 3,P＜0.05).MMP-2与MMP-7、MMP-2与MMP-9表达呈正相关(r=0.302 2,P＜0.01;r =0.2436,P＜0.05),MMP-2与TIMP-1呈负相关(r=-0.262 3,P＜0.05),MMP-9与TIMP-1呈负相关(r=-0.342 5,P＜0.01).结论 胃癌组织中ANXA2蛋白强表达是预后差的指标,ANXA2蛋白可能通过调节MMPs家族成员促进胃癌转移.
目的 探討胃癌組織中膜聯蛋白A2(ANXA2)錶達與胃癌臨床病理特徵及預後的關繫.方法 對96例胃癌手術組織及配對癌徬組織石蠟標本進行免疫組織化學染色(IHC),檢測ANXA2、基質金屬蛋白酶-2(MMP-2)、MMP-7、MMP-9、基質金屬蛋白酶組織抑製劑-1(TIMP-1)的染色,分析其中的關繫;收集胃癌患者臨床病理指標,分析ANXA2與胃癌臨床病理特徵的關繫;所有患者進行隨訪,進行預後分析.結果 胃癌組織中ANXA2錶達暘性率為78.13％(75/96),比癌徬組織的暘性錶達率[28.13％(27/96)]增高(x2 =48.188,P＜0.01);MMP-2、MMP-7、MMP-9在胃癌組織中暘性錶達率分彆為76.04％(73/96)、65.63％(63/96)、85.42％(82/96),均比癌徬組織的暘性錶達率[20.83％(20/96)、32.29％(31/96)、21.88％ (21/96)]增高(x2=58.578,P＜0.01;x2=21.343,P＜0.01;x2 =77.935,P＜0.01),TIMP-1在胃癌組織中錶達暘性率為33.33％(32/96),明顯低于癌徬組織[60.42％(58/96),x2=14.139,P＜0.01].ANXA2暘性錶達與胃癌患者淋巴結轉移、脈管瘤栓有關(x2=40.253,P＜0.01;x2 =5.704,P＜0.05);Kaplan-Meier生存分析顯示,ANXA2陰性錶達的胃癌患者平均生存期為(42.22±4.50)箇月,比ANXA2暘性者的平均生存期[(26.24±2.30)箇月]明顯延長(x2=7.660,P＜0.01).相關分析顯示,胃癌組織中ANXA2與MMP-2、MMP-7呈正相關(r =0.274 8、P＜0.01;r =0.317 5,P＜0.01),ANXA2與TIMP-1呈負相關(r=-0.262 3,P＜0.05).MMP-2與MMP-7、MMP-2與MMP-9錶達呈正相關(r=0.302 2,P＜0.01;r =0.2436,P＜0.05),MMP-2與TIMP-1呈負相關(r=-0.262 3,P＜0.05),MMP-9與TIMP-1呈負相關(r=-0.342 5,P＜0.01).結論 胃癌組織中ANXA2蛋白彊錶達是預後差的指標,ANXA2蛋白可能通過調節MMPs傢族成員促進胃癌轉移.
목적 탐토위암조직중막련단백A2(ANXA2)표체여위암림상병리특정급예후적관계.방법 대96례위암수술조직급배대암방조직석사표본진행면역조직화학염색(IHC),검측ANXA2、기질금속단백매-2(MMP-2)、MMP-7、MMP-9、기질금속단백매조직억제제-1(TIMP-1)적염색,분석기중적관계;수집위암환자림상병리지표,분석ANXA2여위암림상병리특정적관계;소유환자진행수방,진행예후분석.결과 위암조직중ANXA2표체양성솔위78.13％(75/96),비암방조직적양성표체솔[28.13％(27/96)]증고(x2 =48.188,P＜0.01);MMP-2、MMP-7、MMP-9재위암조직중양성표체솔분별위76.04％(73/96)、65.63％(63/96)、85.42％(82/96),균비암방조직적양성표체솔[20.83％(20/96)、32.29％(31/96)、21.88％ (21/96)]증고(x2=58.578,P＜0.01;x2=21.343,P＜0.01;x2 =77.935,P＜0.01),TIMP-1재위암조직중표체양성솔위33.33％(32/96),명현저우암방조직[60.42％(58/96),x2=14.139,P＜0.01].ANXA2양성표체여위암환자림파결전이、맥관류전유관(x2=40.253,P＜0.01;x2 =5.704,P＜0.05);Kaplan-Meier생존분석현시,ANXA2음성표체적위암환자평균생존기위(42.22±4.50)개월,비ANXA2양성자적평균생존기[(26.24±2.30)개월]명현연장(x2=7.660,P＜0.01).상관분석현시,위암조직중ANXA2여MMP-2、MMP-7정정상관(r =0.274 8、P＜0.01;r =0.317 5,P＜0.01),ANXA2여TIMP-1정부상관(r=-0.262 3,P＜0.05).MMP-2여MMP-7、MMP-2여MMP-9표체정정상관(r=0.302 2,P＜0.01;r =0.2436,P＜0.05),MMP-2여TIMP-1정부상관(r=-0.262 3,P＜0.05),MMP-9여TIMP-1정부상관(r=-0.342 5,P＜0.01).결론 위암조직중ANXA2단백강표체시예후차적지표,ANXA2단백가능통과조절MMPs가족성원촉진위암전이.
Objective To investigate the relationship between annexin A2 (ANXA2) with clinicopathological characteristicand prognosiof gastricancer.MethodNinety-six paraffin specimenof cancetissueand tumor-adjacentissuewere obtained postoperatively, and the expression of ANXA2,matrix metalloproteinase (MMP)-2, MMP-7, MMP-9, and tissue inhibitoof metalloproteinase (TIMP)-1 watested by immunohistochemical staining (IHC).Relationship between ANXA2 and MMP-2, MMP-7, MMP-9, TIMP-1 waanalyzed.Clinicopathological indexewere collected, and datof follow-up were also achieved.Relationship between ANXA2 expression and clinicopathological indexewatested, and prognostianalysiwaalso done.ResultPositive expression rate of ANXA2 wa78.13％ (75/96) in gastricancers, which wahighethan thain tumor-adjacentissue[28.13％ (27/96), x2 =48.188, P ＜ 0.01];positive expression rateof MMP-2, MMP-7, MMP-9 were 76.04％ (73/96), 65.63％ (63/96), 85.42％ (82/96) in gastricancers, and in tumor-adjacentissuepositive expression ratewere 20.83％ (20/96), 32.29％ (31/96), 21.88％ (21/96);positive expression rateof MMP-2, MMP-7, MMP-9 were highein gastricancerthan in tumor-adjacentissue(x2 =58.578, P ＜ 0.01;x2=21.343, P ＜ 0.01;x2=77.935, P ＜ 0.01), and positive expression rate of TIMP-1 in gastricancewa33.33％ (32/96), which walowethan in tumor-adjacentissue[60.42％ (58/96), x2 =14.139, P ＜0.01].Strong expression of ANXA2 warelatedl with lymph node metastasis, tumothrombu(x2 =40.253, P ＜ 0.01;x2 =5.704, P ＜ 0.05).Resultof Kaplan-Meieanalysishowed thamean survival time fopatientwith negative ANXA2[(42.22 ±4.50) months] walongethan the patientwith positive ANXA2 expression [(26.24 ± 2.30) months, x2 =7.660, P ＜ 0.01].Correlation analysishowed thathere wapositive relationship between ANXA2 and MMP-2,MMP-7 (=0.274 8, P ＜ 0.01;=0.317 5, P ＜ 0.01), and negative relationship wafound between ANXA2 and TIMP-1 (=-0.262 3, P ＜ 0.05).Also positive relationshipwere found between MMP-2 and MMP-7, MMP-2 and MMP-9 (=0.302 2,P ＜0.01;=0.2436,P ＜0.05);negative relationshipwere found between MMP-2 and TIMP-1, MMP-9 and TIMP-1 (=-0.262 3, P ＜ 0.05;=-0.342 5, P ＜ 0.01).Conclusion Strong expression of ANXA2 can be used aan index fopooreprognosis, and ANXA2 may promote progression of gastricanceby regulating memberof MMPfamily.
